A new generation of fully human anti- CTLA-4 heavy chain-only, Porustobart, shows superior safety in nonclinical study and clinical trials-MedSci.cn

A new generation of fully human anti- CTLA-4 heavy chain-only, Porustobart, shows superior safety in nonclinical study and clinical trials

Rong, J; Ding, L; Chen, F; Zhao, J; He, Y; Rong, Y; Chen, V

TOXICOLOGY LETTERS, 2023; 384 (): S281

科室
- - 订阅+
  - 更多科室
工具
服务